-
Trilaciclib, sold
under the
brand name Cosela, is a
medication used to
reduce the
frequency of chemotherapy-induced bone
marrow suppression. The most...
-
announced that
Pharmacosmos had
completed its
purchase of G1 Therapeutics.
Trilaciclib, a
small molecule CDK4/6 inhibitor, is a first-in-class, FDA-designated...
-
Grants Priority Review to
Trilaciclib to
Treat Patients with SCLC".
Cancer Network. 17
August 2020.
Retrieved 2020-12-04. "
Trilaciclib |
intravenous CDK4/6...
-
Boehringer and G1
Therapeutics announced a co-promotion
agreement for
trilaciclib (Cosela), a CDK4/6
inhibitor designed to
prevent chemotherapy-induced...
- has been FDA
approved for
mediating chemotherapy-induced side effects.
Trilaciclib (V03AF12,
trade name Cosela) was
approved in
February 2021 to reduce...
-
Cyclin D3/CDK6 activity. G1
Therapeutics also has a CDK4/6 inhibitor,
trilaciclib,
which is up for FDA
approval (target
decision date of
February 15, 2021)...
-
trial data
analysed results in a way that
disfavoured amphotericin B.
Trilaciclib, a CDK4/6 inhibitor,
administered approximately thirty minutes before...
- as a
treatment of chemotherapy-induced myelosuppression/Neutropenia.
Trilaciclib (COSELA), a CDK4/6 inhibitor, is
administered before chemotherapy in...
-
counteract depression of the
immune system in
people undergoing chemotherapy.
Trilaciclib is an
inhibitor of cyclin-dependent
kinase 4/6
approved for the prevention...
-
Vismodegib CDK
inhibitors Abemaciclib Dalpiciclib Palbociclib Ribociclib Trilaciclib KRAS
inhibitors Adagrasib Sotorasib Pi3K
inhibitors Alpelisib Copanlisib...
